We are live on ! Find out more
TGI

TRV GP III Portfolio holdings

AUM $6.14M
1-Year Est. Return 45.44%
This Fund
S&P 500
This Quarter Est. Return
-10.71%
1 Year Est. Return
+45.44%
3 Year Est. Return
+169.98%
5 Year Est. Return
+802.39%
10 Year Est. Return
–
AUM
$286M
AUM Growth
–
Cap. Flow
+$286M
Cap. Flow %
100.24%
Top 10 Hldgs %
100%
Holding
4
New
4
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
VYGR icon
Voyager Therapeutics
VYGR
+$161M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$57.7M
3
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$44.8M
4
EDIT icon
Editas Medicine
EDIT
+$22.8M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
1
Voyager Therapeutics
VYGR
$189M
$156M 54.58%
+9,391,176
New +$161M
MYOK
2
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$63M 22.06%
+1,496,598
New +$57.7M
JNCE
3
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$38.9M 13.61%
+3,048,780
New +$44.8M
EDIT icon
4
Editas Medicine
EDIT
$445M
$27.8M 9.75%
+906,176
New +$22.8M

Similar funds

TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
GIP
General Industrial Partners London, United Kingdom $2.57M AUM
LCMP
Linse Capital Management PR San Juan, Puerto Rico $2.31M AUM
SCM
SevenOneSeven Capital Management Lancaster, Pennsylvania $2.17M AUM 8.67% 1-Year Est. Return
TA
Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

TRV GP III's Q4 2017 Portfolio in Review

Q4 2017 is the first quarter with a 13F filing on record for TRV GP III, which disclosed 4 positions worth $286M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Voyager Therapeutics: 9,391,176 shares worth $156M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • TRV GP III's largest Q4 2017 buy was Voyager Therapeutics: 9,391,176 shares worth $156M.
  • TRV GP III's ten largest holdings make up 100% of its $286M portfolio in Q4 2017.
  • TRV GP III disclosed 4 positions in Q4 2017, its first 13F filing on record.

Based on TRV GP III's 13F filing for Q4 2017, filed 13 Feb 2018.